SCHEMBL5864124

SCHEMBL5864124

Cc1nc2ccc(N3CCNCC3)cc2c(=O)n1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.54
KDM4E B2RXH2 6/20 0.52
ALDH1A1 P00352 6/20 0.52
HPGD P15428 3/20 0.52
HSD17B10 Q99714 3/20 0.52
MAPT P10636 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HTT P42858 2/20 0.52
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C9 P11712 1/20 0.52
ALOX15 P16050 1/20 0.52
CASP1 P29466 1/20 0.52
CYP2C19 P33261 1/20 0.52
SOS1 Q07889 1/20 0.51
DPP4 P27487 3/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5863458 0.81 HTR1A (0.52) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL31196722 0.77 SMN1; SMN2 (0.70) KDM4EALDH1A1HPGDHSD17B10MAPT
SCHEMBL5863348 0.76 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL5864286 0.74 HTR2C (0.51) HTR6ALDH1A1HSD17B10MAPTMEN1
SCHEMBL14159142 0.73 SMN1; SMN2 (0.55) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL5864193 0.72 MEN1 (0.88) ALDH1A1HPGDSMN1; SMN2MEN1KMT2A
SCHEMBL1882530 0.71 SMN1; SMN2 (0.62) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL5864222 0.71 TDO2 (0.55) ALDH1A1HPGDMAPTSMN1; SMN2LMNA
SCHEMBL18668327 0.70 HTR6 (1.00) HTR6
SCHEMBL12789801 0.70 MEN1 (0.64) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7030120-B2 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-18 US disclosed
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same OHKURA NAOTO (JP) 2004-11-11 US disclosed
US-6777414-B1 INHIBITORS OF TRIGLYCERIDE BIOSYNTHESIS AND SECRETION OF APOLIPOPROTEIN B-CONTAINING LIPOPROTEINS; ARTERIOSCLEROTIC DISEASES; HYPERLIPIDEMIA MEIJI SEIKA KAISHA, LTD. (JP) 2004-08-17 US disclosed
EP-1180514-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND BENAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2002-02-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224959-A1 Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same APOB, NCEH1, LIPC HTR6 1531/4885KDM4E 2536/4885ALDH1A1 1345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.